Completed PHASE2 INTERVENTIONAL 4-arm NCT00336479

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions Chronic Hepatitis C

Interventions Pegylated Interferon Alfa 2a Placebo Ribavirin Telaprevir

Updated 7 times since 2017 Last updated: Jun 25, 2014 Started: Jun 30, 2006 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00336479, this PHASE2 trial focuses on Chronic Hepatitis C and remains completed. Sponsored by Vertex Pharmaceuticals Incorporated, it has been updated 7 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vertex Pharmaceuticals Incorporated

Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Annandale, United States , Baltimore, United States , Baton Rouge, United States , Boston, United States , Chapel Hill, United States , Charlotteville, United States , Chicago, United States , Cincinnati, United States , Dallas, United States and 22 more locations